DB:42P

Stock Analysis Report

Executive Summary

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Proteostasis Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 42P's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.5%

42P

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

-83.1%

42P

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: 42P underperformed the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 42P underperformed the German Market which returned 9.9% over the past year.


Shareholder returns

42PIndustryMarket
7 Day11.5%-2.3%0.03%
30 Day41.5%-3.1%4.4%
90 Day64.7%-9.6%13.6%
1 Year-83.1%-83.1%-6.7%-6.9%13.4%9.9%
3 Year-91.4%-91.4%52.7%50.8%25.6%14.6%
5 Yearn/a5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is Proteostasis Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Proteostasis Therapeutics undervalued compared to its fair value and its price relative to the market?

0.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 42P's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 42P's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 42P is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 42P is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 42P's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 42P is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Proteostasis Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

27.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 42P is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 42P is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 42P is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 42P's revenue (71.7% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 42P's revenue (71.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 42P's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Proteostasis Therapeutics performed over the past 5 years?

-21.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if 42P has high quality earnings.

Growing Profit Margin: 42P's current net profit margins (-1283.4%) are higher than last year (-1307.8%).


Past Earnings Growth Analysis

Earnings Trend: 42P is unprofitable, and losses have increased over the past 5 years at a rate of -21.8% per year.

Accelerating Growth: Unable to compare 42P's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 42P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 42P has a negative Return on Equity (-91.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Proteostasis Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 42P's short term assets ($79.7M) exceeds its short term liabilities ($11.6M)

Long Term Liabilities: 42P's short term assets (79.7M) exceeds its long term liabilities (12.3M)


Debt to Equity History and Analysis

Debt Level: 42P is debt free.

Reducing Debt: 42P currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 42P has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 42P's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 42P has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 42P has sufficient cash runway for 1.220674 years if free cash flow continues to reduce at historical rates of -13.6% each year.


Next Steps

Dividend

What is Proteostasis Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 42P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 42P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 42P's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 42P's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 42P's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Proteostasis Therapeutics's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Meenu Chhabra (47yo)

5.5yrs

Tenure

US$1,289,270

Compensation

Ms. Meenu Chhabra has been the Chief Executive Officer and President at Proteostasis Therapeutics, Inc. since May, 2014. Ms. Chhabra's initial focus is driving the development of Proteostasis' cystic fibro ...


CEO Compensation Analysis

Compensation vs Market: Meenu's total compensation ($USD1.29M) is above average for companies of similar size in the German market ($USD215.84K).

Compensation vs Earnings: Meenu's compensation has been consistent with company performance over the past year.


Management Age and Tenure

0.8yrs

Average Tenure

50yo

Average Age

Experienced Management: 42P's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 42P's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.6%.


Management Team

  • Meenu Chhabra (47yo)

    President

    • Tenure: 5.5yrs
    • Compensation: US$1.29m
  • Geoff Gilmartin (51yo)

    Chief Medical Officer

    • Tenure: 0.8yrs
  • Sheila Wilson (61yo)

    Chief Operating Officer

    • Tenure: 0.8yrs
  • Po-Shun Lee (50yo)

    Consultant

    • Tenure: 4.5yrs
    • Compensation: US$647.77k
  • Ben Munoz (57yo)

    Chief Scientific Officer

    • Tenure: 2.7yrs
    • Compensation: US$646.68k
  • Eric Larson (49yo)

    Principal Financial Officer & Principal Accounting Officer

    • Tenure: 0.5yrs
  • Masha Zecevic (45yo)

    Chief Commercial Officer

    • Tenure: 0.8yrs
  • Sandra Zimmerman

    Consultant

    • Tenure: 0.5yrs
  • Claudia Styslinger

    Investor Relations Executive

    • Tenure: 0yrs

Board Members

  • Meenu Chhabra (47yo)

    President

    • Tenure: 5.5yrs
    • Compensation: US$1.29m
  • David Arkowitz (58yo)

    Director

    • Tenure: 0.7yrs
  • Franklin Berger (70yo)

    Chairman

    • Tenure: 0.8yrs
    • Compensation: US$82.66k
  • F. Hartl

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Bill Morimoto

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kim Drapkin (51yo)

    Director

    • Tenure: 0.8yrs
  • Daniel Finley

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jeffery Kelly (59yo)

    Director & Member of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$126.16k
  • Randall King

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Richard Moss

    Chairman of Clinical Advisory Board

    • Tenure: 0yrs

Company Information

Proteostasis Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Proteostasis Therapeutics, Inc.
  • Ticker: 42P
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$53.685m
  • Listing Market Cap: US$48.596m
  • Shares outstanding: 51.13m
  • Website: https://www.proteostasis.com

Number of Employees


Location

  • Proteostasis Therapeutics, Inc.
  • 80 Guest Street
  • Suite 500
  • Boston
  • Massachusetts
  • 2135
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTINasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2016
42PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2016

Biography

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 21:48
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.